RxDoctor Payments Data

Gautham Viswanathan, MD

Nephrology · Atlanta, GANPI 1427194257

Payments from drug & device makers

$9,655in general payments, 2019–2025

Across 164 payments — averaging $58.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$4K
  • Travere Therapeutics, Inc.$4K
  • Fresenius USA Marketing, Inc.$445
  • Akebia Therapeutics Inc$347
  • Novartis$281
  • Novo Nordisk$259
  • plus $920 from 16 others

What the payments were for

  • Consulting fees$3,44436%
  • Speaking & faculty fees$2,70028%
  • Travel & lodging$5776%
  • Food & beverage$2,75128%
  • Education$1832%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,655 in reported general payments places this provider in the 80th percentile of 388 nephrology providers in Georgia.

See all nephrology providers in Georgia

Medicare billing

Part B allowed, 2024
$225,983
Medicare patients
575
Services billed
2,542

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol183$183,831
JardianceEmpagliflozin164$170,436
VeltassaPatiromer Calcium Sorbitex111$163,687
KerendiaFinerenone85$96,923
VelphoroSucroferric Oxyhydroxide24$83,807
LokelmaSodium Zirconium Cyclosilicate72$76,711
Potassium Citrate ErPotassium Citrate38$4,439
Cinacalcet Hcl17$3,949
Nebivolol Hcl61$3,180
Nifedipine ErNifedipine87$3,101
Eplerenone20$2,960
Torsemide131$2,047
Sevelamer Carbonate11$1,970
Hydralazine Hcl138$1,931
Doxazosin Mesylate103$1,919

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$142$260,543255 claims
BayerKerendia$136$96,92385 claims
Fresenius USA Marketing, Inc.Velphoro$445$83,80724 claims
ANI Pharmaceuticals, Inc.Valsartan$23$1,34333 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 388 nephrology providers in Georgia.

Other nephrology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →